Status:
COMPLETED
Psychobiological Mechanisms Underlying Chronic Pain
Lead Sponsor:
susanne becker
Collaborating Sponsors:
SNSF
Conditions:
Fibromyalgia
Pain, Chronic
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Pain is a powerful motivator of behavior and it is more than the perception of nociceptive input. It is a complex experience that comprises different components: sensory discriminative, emotional-moti...
Detailed Description
Pain is a powerful motivator of behavior and it is more than the perception of nociceptive input. It is a complex experience that comprises different components: sensory discriminative, emotional-moti...
Eligibility Criteria
Inclusion
- For fibromyalgia patients:
- Inclusion criteria:
- Age between 18 to 70 years
- Chronic widespread pain
- Symptoms such as fatigue, cognitive dysfunction, and/or depressive symptoms
- Sufficient knowledge of German or English to follow instructions
- Ability to give written informed consent
- Exclusion criteria:
- Psychiatric or neurological disorders, except depression and anxiety
- Substance abuse or consumption of alcohol, illegal drugs, analgesics apart from prescribed routine medication within the last 24 h before testing session
- Pacemaker or metal parts in the body or any contradictions to MRI
- Pregnancy and breast-feeding
- Medical history indicating any risk/allergies using the amisulpride or bromocriptine or both or other ergotamine. Long QT syndrome, cardiac arrhythmia, intake of drugs causing QT prolongation in the electrocardiogram.
- Liver or/and kidney problems
- High blood pressure or cardiovascular or heart disease
- Stomach ulcers or bleeding
- Fibrosis
- Diabetes
- Cancer patients
- Intake of drugs lowering potassium levels in the blood
- Blood pressure problems during pregnancy in the past
- History of breast cancer in the family first-order relatives
- Cerebrovascular events in anamnesis
- Simultaneous intake of potent or moderate Cytochrome P450 inhibitors
- For Healthy participants:
- Inclusion criteria:
- Age-matched healthy participants
- Good overall health status
- Sufficient knowledge of German or English to follow instructions
- Ability to give written informed consent
- Exclusion criteria:
- Pain longer than 3 consecutive days and on more than 30 days within the last 12 months
- Major psychiatric or neurological disorders
- Pregnancy and breast-feeding
- Substance abuse or consumption of alcohol, illegal drugs, and analgesic drugs within 24 h before testing session
- Pacemaker or metal parts in the body or any contradiction to MRI
- Medical history indicating any risk/allergies using the amisulpride or bromocriptine or both or other ergotamine.
- Liver or/and kidney problems
- High blood pressure or cardiovascular or heart disease
- Stomach ulcers or bleeding
- Fibrosis
- Diabetes
- Low potassium levels in the blood
- Blood pressure problems during pregnancy in the past
- History of breast cancer in first-order relatives
- Cerebrovascular events in anamnesis
- Simultaneous intake of potent or moderate Cytochrome P450 inhibitors
Exclusion
Key Trial Info
Start Date :
November 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2023
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04674670
Start Date
November 1 2021
End Date
July 31 2023
Last Update
September 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Balgrist Campus
Zurich, Switzerland, 8008